ASSESSMENT OF POTENTIAL COCAINE TREATMENT MEDICATIONS

潜在可卡因治疗药物的评估

• 批准号: 2709797
• 负责人: MICHAEL J. FORSTER
• 金额: $ 37.09万
• 依托单位: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2709797
• 关键词: chordate locomotion; cocaine; drug abuse chemotherapy; drug screening /evaluation; laboratory mouse; laboratory rat

This represents a competitive renewal of NIDA contract N01DA29305, entitled "Assessment of Potential Cocaine Treatment Medications in Rodents". The objectives of this research and development contract is to determine the effects of compounds in the rodent locomotor activity and drug discrimination procedures as a means of evaluating their potential efficacy as cocaine treatment medications. These tests have been selected by NIDA Medication Development Division's (MDD) Cocaine Treatment Discovery Program (CTDP) because they are believed to represent model systems that may be predictive of clinical efficacy of pharmacotherapies for cocaine dependence. The data generated by this contract will be utilized by the NIDA/MDD/CTDP in the selection of compounds for additional preclinical evaluation and subsequent development as pharmacotherapies for cocaine dependence. Briefly, the Contractor will be screening compounds in the mouse locomotor activity and rat drug discrimination test. We respect to the locomotor activity procedure, the effect of the compound, administered alone and in combination with cocaine, on locomotor activity in mice will be assessed. Depending on results obtained from the locomotor activity test, the compound will either be evaluated for the ability to antagonize the discriminative (subjective) effects of cocaine or to substitute for the discriminative (subjective) effects of cocaine. The anticipated end results of this contract will be written reports detailing study findings.

这代表了NIDA合同N 01 DA 29305的竞争性续约， 题为“评估潜在的可卡因治疗药物， 啮齿动物”。 这项研究和开发合同的目的是 以确定化合物在啮齿动物运动活动中的作用 和药物歧视程序作为评估其 作为可卡因治疗药物的潜在功效。 这些试验 NIDA药物开发部（MDD） Coconut治疗发现计划（CTDP），因为他们是 被认为代表了可以预测临床疾病的模型系统。 药物治疗对可卡因依赖的疗效。 数据 NIDA/MDD/CTDP将使用本合同产生的信息， 选择用于额外临床前评价的化合物， 作为可卡因药物疗法的后续发展 依赖 简而言之，承包商将筛选 小鼠自发活动和大鼠药物辨别试验。 我们 关于自发活动程序， 化合物单独给药和与可卡因联合给药， 评价小鼠的自发活动。 根据结果 从自发活动试验获得的化合物， 评价对抗歧视性（主观） 可卡因的影响或替代歧视性（主观） 可卡因的影响。 该合同的预期最终结果将是 详细说明研究结果的书面报告。